Anti-Mouse CD120a (TNFR1) [Clone 55R-593] — Purified in vivo GOLD™ Functional Grade

Clone 55R-593 is primarily used in vivo in mice as a specific blocker of TNFR1 signaling. The common applications of this clone include:

• Blocking ligand-induced receptor signaling: Clone 55R-593 is used to inhibit the signaling through TNFR1, which is crucial in studying inflammation, immunity, and disease models.
• Immunoprecipitation (IP) and Western Blot (WB): Although these methods are typically used in vitro, the antibody has been reported to work well in these applications, facilitating the detection and analysis of proteins in laboratory settings.
• In vivo receptor blocking: This involves using the antibody to block TNFR1 signaling in live mice, allowing researchers to study the role of TNFR1 in various physiological and pathological processes.

Overall, clone 55R-593 is a versatile tool for understanding TNF receptor biology in both in vitro and in vivo contexts.

Commonly used antibodies or proteins with 55R-593 (anti-mouse CD120a/TNFR1) in the literature generally relate to similar functional studies of TNF signaling, inflammation, apoptosis, and cell signaling pathways.

Key antibodies and proteins often used together with 55R-593 include:

• Signaling pathway markers:

  • Anti-phospho-NF-κB
  • Anti-phospho-ERK
  • These are used to analyze downstream signaling cascades activated upon TNFR1 engagement.

• Apoptosis markers:

  • Anti-cleaved caspase-3
  • Annexin V
  • Used to assess cell death and apoptosis resulting from TNFR1 stimulation or blockade.

• Inflammatory markers:

  • Anti-ICAM-1
  • Anti-VCAM-1
  • These monitor inflammatory responses in tissue or cell models where TNFR1 is manipulated.

• Isotype controls and detection reagents:

  • A biotinylated anti-Armenian hamster IgG is commonly used as a secondary antibody when detecting 55R-593, since this antibody is an Armenian hamster IgG.
  • Streptavidin-PE or similar conjugates are used in multi-layer detection protocols to maximize signal.

• Standard cell markers and controls:

  • Loading controls in western blotting, such as anti-actin, anti-tubulin, and anti-GAPDH, are frequently reported in studies employing 55R-593 to ensure data normalization.

Functional context:
55R-593 is generally used to manipulate or study the TNF/TNFR1 pathway in mouse models, often in combination with the antibodies above to dissect signaling mechanisms, cell death, or inflammation.

If you are following published protocols, these are the most frequently co-applied antibodies with 55R-593 across assays involving signaling characterization, immunofluorescence, western blot, or flow cytometry.

Key findings from scientific literature on clone 55R-593 center on its unique functional properties as an antibody targeting mouse CD120a (TNFR1). The most notable findings include:

• Agonist Activity: Unlike other anti-p55 (CD120a) antibodies, clone 55R-593 can act as an agonist. It is capable of triggering cell lysis, promoting nitric oxide induction, and activating NF-κB, thereby initiating various downstream signaling pathways.

• Blocking and Modulation: The antibody is also reported to be useful for in vitro and in vivo receptor blocking of TNF-α and TNF-β (LT-α) signaling, indicating that it can both mimic and inhibit native ligand activities depending on experimental conditions.

• Experimental Applications: Clone 55R-593 is widely used in immunoprecipitation (IP), western blotting (WB), and in vivo functional studies to dissect the contribution of TNFR1 signaling in a range of immunological and cell death processes.

• Mechanistic Insights: Engagement of TNFR1 by 55R-593, particularly in association with the adaptor proteins TRADD and RIP, can induce apoptosis, NF-κB activation, proinflammatory gene expression, and variable cell fates depending on cell type and context.

• Comparative Findings: Literature highlights that 55R-593 differs functionally from other anti-TNFR1 clones (e.g., 55R-170, 55R-176), due to its agonist potential in addition to possible antagonistic effects, offering versatility for mechanistic studies on TNF signaling.

• Reagent Quality: The antibody is available in high-purity, low-endotoxin formulations for in vivo and in vitro use, and is recommended for functional studies involving TNFR1 modulation.

In summary, clone 55R-593 is a multipurpose tool in TNF biology, allowing researchers to selectively activate or inhibit TNFR1-dependent signaling for studies on inflammation, apoptosis, and immune responses.

Dosing regimens of clone 55R-593 (anti-mouse CD120a/TNFR1) can vary substantially across mouse models, largely depending on the application (such as blocking vs. agonism), experimental objectives, and sometimes the specific disease setting or mouse strain. There is no single universal dosing protocol; instead, regimens are typically tailored empirically for each study.

Key factors influencing dosing regimens:

• Application type: For receptor blocking, lower or repeated dosing may be used; for agonist studies, higher single or pulsed doses might be applied.
• Experimental goal: Studies assessing acute vs. chronic effects, or different disease models (e.g., inflammation, cancer, autoimmune disease), may require adjusted dose amounts and scheduling.
• Mouse strain/disease model: Some strains or disease contexts might necessitate dose titration to achieve efficacy without off-target toxicity.

Reported Uses and Considerations:

• Clone 55R-593 is reported for both in vivo receptor blockade and as an agonist of TNF-α signaling.
• No standardized dose is universally published for this antibody in vivo—the dose, frequency, and route of administration (usually intraperitoneal) are typically established by empiric titration based on pilot data and study-specific needs.
• Standard practices for functional antibodies (not specific to 55R-593 but referenced for context) in murine studies typically use doses ranging from 100–500 μg per mouse, administered intraperitoneally, every 2–7 days depending on antibody and disease model. However, these are general reference ranges for similar in vivo antibodies, not specific to 55R-593.

Summary Table: Regimen Determinants for 55R-593 in Mice

Most studies and antibody vendors recommend empirically determining the optimal dosing schedule for clone 55R-593 in the specific experimental context.

No explicit multi-model comparison or detailed regimen table for 55R-593 was found in the current search results, indicating that direct comparative data across different mouse models is either unpublished or resides in primary research literature not captured here. Experimenters are advised to use published protocols as a starting point and adjust empirically for their particular mouse model.